**Core tip:** Vascular complications after anterior cruciate ligament (ACL) reconstruction of the knee may present serious morbidity and even mortality. Although rare, it is necessary to understand the main risks and symptoms of these devastating lesions. This systematic review presents the current knowledge on arterial injuries, venous thromboembolism and thromboprophylaxis after ACL reconstruction.

INTRODUCTION
============

Vascular complications after anterior cruciate ligament (ACL) reconstructions cause serious morbidity and potential mortality\[[@B1]\]. They can be categorized in arterial and venous thromboembolic complications. The incidence of arterial complications after ACL reconstruction is unknown\[[@B1]\]. Case reports have been published using various techniques of ACL reconstruction\[[@B1]\].

Venous thromboembolism (VTE) after ACL reconstruction may present clinically as symptomatic or asymptomatic deep venous thrombosis (DVT), pulmonary embolism (PE) and postthrombotic syndrome\[[@B1]-[@B3]\]. The incidence of VTE after ACL reconstruction varies from 0.2%-14%\[[@B1],[@B2],[@B4]-[@B11]\]. The variable incidence of VTE after ACL reconstruction depends on the diagnostic methods of DVT (clinical parameters, venography, ultrasound or magnetic resonance venography), the heterogeneity of patient demographics (age, risk factors, surgical time, concomitant surgery, tourniquet time and postoperative mobilisation) and DVT prophylaxis\[[@B1],[@B12]\]. Deep venous thrombosis may cause pulmonary embolism which may be fatal in its immediate course or may result in pulmonary hypertension in the long term\[[@B1],[@B13]\]. The postthrombotic syndrome may cause serious morbidity and affects 23% of limbs 2 years after DVT, 35%-69% and 49%-100% at 3 and at 5-10 years respectively\[[@B1],[@B4],[@B14]\]. ACL reconstruction ranks number 6 of most performed orthopedic operations\[[@B15]\]. However uniform evidence-based clinical practice guidelines for DVT prophylaxis after ACL reconstruction are lacking\[[@B1],[@B2],[@B16]\].

A thorough understanding of the incidence, risk factors and potential methods for prevention of vascular complications after ACL reconstruction is critical to optimize patient safety\[[@B17]\]. This systematic review presents the current knowledge of arterial complications, VTE and thromboprophylaxis after arthroscopic ACL reconstruction. The review will highlight the incidence, types and risk factors of arterial complications and VTE after ACL reconstruction as well as the current recommendations for DVT prophylaxis.

MATERIALS AND METHODS
=====================

The reporting in this systematic review was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement\[[@B18]\].

Eligibility criteria
--------------------

Inclusion criteria were all study designs evaluating arterial complications and VTE after ACL reconstruction. Any arthroscopic surgical method of primary or revision intra-articular ACL reconstruction of all graft types was included. Only human *in vivo* studies were eligible for inclusion in the systematic review. The full inclusion and exclusion criteria are presented in Table [1](#T1){ref-type="table"}.

###### 

Inclusion and exclusion criteria

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Inclusion criteria
  Studies (randomized, non-randomized, case series, prospective or retrospective design, case reports) evaluating vascular and thromboembolic complications after ACL reconstruction
  All types of ACL reconstruction surgery related arterial and venous complications
  All types of ACL reconstruction surgery related thromboembolic complications
  Any arthroscopic surgical method of primary or revision intra-articular ACL reconstruction
  All graft types for ACL reconstruction
  Multiligament reconstructions including ACL
  Combined ACL reconstruction and meniscal surgery
  Human *in vivo* studies with reported outcome
  English language
  Full text available
  Exclusion criteria
  Animal studies
  Cadaveric studies
  Nonsurgical related vascular or thromboembolic complications
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACL: Anterior cruciate ligament.

Electronic search
-----------------

MEDLINE, EMBASE, Cochrane, Web of Science, CINAHL, PubMed publisher, and Google scholar medical literature databases were searched up to November 10, 2015. Search terms included synonyms for anterior cruciate ligament reconstruction, and synonyms for vascular complications. Additionally, the reference lists of all eligible studies were manually screened.

Study selection
---------------

All eligible articles were screened by title and abstract by 2 teams of reviewers. One author screened all abstracts and 2 co-authors scored both half of the abstracts independently of the first author. After this first inclusion, the full-text articles were assessed. Disagreements on inclusions were resolved by discussion and, if necessary, a final decision was made by a fourth reviewer. Furthermore, all references of both excluded and included articles were analyzed for eligible articles. The consequences of the search strategy (screening of title and abstract) are that only those studies will be eligible for inclusion if arterial complications, VTE or DVT prophylaxis after ACL reconstruction are reported in the abstracts. Studies that did not report these findings in their abstract were consequently not included in the current review.

Data collection process
-----------------------

Two reviewers extracted the study characteristics, type of vascular complications, and if available the incidence of vascular complications in the study population.

Data items
----------

The data included study type, patient demographics, type and incidence of vascular or thromboembolic complication (arterial, pulmonary embolism, symptomatic or asymptomatic DVT), surgical technique, graft type, graft fixation method, thromboprophylaxis, tourniquet time and pressure and comorbidity for vascular and thromboembolic complications.

Synthesis of results
--------------------

Incidence of DVT (separated for all and symptomatic) and PE was pooled of the studies reporting data of isolated ACL reconstruction without thromboprophylaxis. Additionally, the incidence numbers of those studies with low risk of bias on the items patient selection and classification were pooled.

Assessment of risk of bias
--------------------------

Risk of bias was assessed in the studies used for the determination of the incidence of vascular and/or venous complications following an ACL reconstruction procedure. Risk of bias was not assessed for case reports. Two reviewers independently assessed the risk of bias of the studies. In case of disagreement, the two reviewers tried to achieve consensus. If consensus was not achieved, a third reviewer was asked for final judgment. Those items of the checklist of the Dutch Cochrane Centre of risk of bias of studies reporting the incidence of adverse events, suitable for the current study objectives, were used for the risk of bias assessment\[[@B19]\]. All items could be rated "positive" (+), "negative" (-) or "not clear" (?).

Studies were classified as low risk of selection bias when they scored "positive" on the item: "The authors reported inclusion of 'all' or 'consecutive' patients". Studies were classified as low risk of information bias when they scored "positive" on the items: "Follow-up period was minimally 1 year" and "if all included patients were evaluated for complications".

Research questions
------------------

The following research questions were formulated.

**Arterial complications:** (1) What is the incidence of arterial complications after ACL reconstruction? (2) What types of arterial complications occur after ACL reconstruction? (3) Is there a correlation between arterial complications and fixation methods for ACL reconstruction? (4) What is the time to diagnosis of arterial complications after ACL reconstruction?

**Venous complications:** (1) What is the incidence of VTE after ACL reconstruction without thromboprophylaxis? (2) Is tourniquet time related to VTE after ACL reconstruction? (3) Is thromboprophylaxis indicated after ACL reconstruction?

RESULTS
=======

Study selection
---------------

The PRISMA flow chart of the systematic review is presented in Figure [1](#F1){ref-type="fig"}. A total of 47 studies were included: 2 randomized controlled trials (RCT)\[[@B20],[@B21]\], 8 prospective cohort studies\[[@B5],[@B6],[@B10],[@B11],[@B22]-[@B25]\], 9 retrospective cohort studies\[[@B2],[@B4],[@B7],[@B8],[@B26]-[@B30]\] and 28 case reports\[[@B13],[@B31]-[@B57]\].

![Prisma flow chart. ACL: Anterior cruciate ligament.](WJO-7-604-g001){#F1}

Risk of bias assessment
-----------------------

The results of the risk of bias assessment for the included studies are presented in Table [2](#T2){ref-type="table"}. Case reports were not eligible for risk of bias assessment.

###### 

Risk of bias of studies reporting venous complications

  **Ref**.                        **Study design**   **Patient selection[1](#T2FN1){ref-type="table-fn"}**   **Follow-up[2](#T2FN2){ref-type="table-fn"}**   **Classification[3](#T2FN3){ref-type="table-fn"}**
  ------------------------------- ------------------ ------------------------------------------------------- ----------------------------------------------- ----------------------------------------------------
  Adala et al\[[@B6]\]            PC                 \+                                                      \-                                              \+
  Born et al\[[@B26]\]            RS                 \+                                                      \-                                              \-
  Cullison et al\[[@B10]\]        PC                 ?                                                       \-                                              \+
  Dong et al\[[@B8]\]             RS                 ?                                                       \-                                              \+
  Ettema et al\[[@B27]\]          RS                 \-                                                      ?                                               \-
  Gaskill et al\[[@B2]\]          RS                 \+                                                      \-                                              \-
  Hetsroni et al\[[@B30]\]        RS                 ?                                                       ?                                               \-
  Hirota et al\[[@B22]\]          PC                 \-                                                      \-                                              \+
  Hirota et al\[[@B25]\]          PC                 \-                                                      \-                                              \+
  Jameson et al\[[@B28]\]         RS                 ?                                                       \-                                              \-
  Jaureguito et al\[[@B7]\]       RS                 \+                                                      \-                                              \+
  Lind et al\[[@B23]\]            PC                 \+                                                      ?                                               \-
  Maletis et al\[[@B11]\]         PC                 ?                                                       ?                                               \-
  Marlovits et al\[[@B20]\]       RCT                \-                                                      \-                                              \+
  Mohtadi et al\[[@B21]\]         RCT                \+                                                      \+                                              \-
  Struijk-Mulder et al\[[@B5]\]   PC                 \+                                                      \-                                              \+
  Sun et al\[[@B29]\]             RS                 \+                                                      \-                                              \+
  Williams et al\[[@B24]\]        PC                 \-                                                      \-                                              \+
  Ye et al\[[@B4]\]               RS                 ?                                                       \-                                              \+

Inclusion of consecutive patients;

Was follow-up period adequate (minimum 1 year) for exposure of adverse event?

Was the used classification shown to be valid and reliable? +: Yes; -: No; ?: Not clear; RCT: Randomized controlled trial; PC: Prospective cohort study; RS: Retrospective study.

Details of arterial complications and thromboprophylaxis
--------------------------------------------------------

The results of the arterial complications are specified in Table [3](#T3){ref-type="table"}. The details of VTE and thromboprophylaxis are detailed in Table [4](#T4){ref-type="table"}. Table [5](#T5){ref-type="table"} presents the incidence of DVT and PE after pooling the data for isolated ACL reconstructions without thromboprophylaxis.

###### 

Results arterial injuries (case reports)

  **Ref**.                        **ACLR**     **Graft type**                  **Fixation femur**   **Fixation tibia**         **Vascular injury**                                    **Diagnosis after ACLR**   **Treatment**             **Cause vascular complication**
  ------------------------------- ------------ ------------------------------- -------------------- -------------------------- ------------------------------------------------------ -------------------------- ------------------------- -----------------------------------------------------------
  Spalding et al\[[@B31]\]        Primary      Gore-Tex                        ?                    ?                          Compression popliteal artery                           8 yr                       Cyst removal              Compression by cyst containing ruptured Gore-tex graft
  Aldridge et al\[[@B32]\]        Primary      BPTB                            Interference screw   Interference screw         Avulsion middle gen. artery                            4 wk                       Direct repair avulsion    Lesion artery by shaver
  Evans et al\[[@B33]\]           Primary      BPTB                            Interference screw   Interference screw         Pseudoaneurysm med. inf. gen. artery                   5 wk                       Ligation pseudoaneurysm   Elevation periosteum medial tibia (tunnel preparation)
  Friederich et al\[[@B34]\]      Primary      BPTB                            Staples              Staples                    Lesion sup. lat. gen. artery                           5 mo                       Removal staples           Hardware femur
  Kanko et al\[[@B35]\]           Primary      BPTB                            Interference screw   Bicortical screw           Pseudoaneurysm popliteal artery                        2 yr                       Ligation pseudoaneurysm   Drill bit for bicortical tibia fixation?
  Keçeci et al\[[@B36]\]          Primary      BPTB                            Interference screw   Interference screw         Popliteal arteriovenous fistula                        18 mo                      Venous re-anastomosis     Break-out posterior femoral cortex
  Lamo-Espinosa et al\[[@B37]\]   Primary      BPTB                            Interference screw   Interference screw         Lesion lat. inf. gen. artery                           1 d                        Embolization              Simultaneous lateral meniscectomy
  Mello et al\[[@B38]\]           Primary      BPTB                            Interference screw   Interfererce screw         Pseudoaneurysm med. inf. gen. artery                   6 wk                       Embolization              Direct lesion artery by shaver
  Pereira et al\[[@B39]\]         Primary      BPTB                            Interference screw   Interference screw         Pseudoaneurysm sup. lat. gen. artery                   11 d                       Ligation pseudoaneurysm   Hardware femur
  Roth et al\[[@B40]\]            Primary      BTPB + augmentation             Staple               ?                          Occlusion popliteal artery                             6 wk                       Venous bypass             Entrapment between graft and femur
  Tam Kelvin et al\[[@B41]\]      Primary      BPTB                            Endobutton           Interference screw         Pseudoaneurysm popliteal artery                        8 d                        Repair by venous graft    Direct trauma by guide pin femoral canal
  Lee et al\[[@B42]\]             Rerevision   ?                               Rigidfix cross pin   ?                          2 lesions sup. to level of med. and lat. gen. artery   6 wk                       Venous re-anastomosis     Drill tip for Rigidfix cross pin
  Ambrosia et al\[[@B57]\]        Primary      Hamstring                       TightRope            Interference screw         Pseudoaneurysm popliteal artery                        7 wk                       Venous bypass             Hamstring harvest/previous catheterization-angioplasty?
  Buda et al\[[@B43]\]            Primary      Hamstring ACL + allograft PCL   Staples              Staples                    Pseudoaneurysm post. tibial artery                     1 wk                       Embolization              Surgical approach PCL or hamstring harvest?
  Galanakis et al\[[@B44]\]       Primary      Hamstring + extra-artic. rec.   Staples              Pes anserinus              Pseudoaneurysm popliteal artery                        Day of surgery             Venous re-anastomosis     Lesion artery by shaver and popliteal entrapment syndrome
  Janssen et al\[[@B45]\]         Primary      Hamstring                       Bone Mulch Screw     WasherLoc                  Pseudoaneurysm popliteal artery                        12 d                       Venous repair             Drill tip for bicortical tibial fixation
  Janssen et al\[[@B47]\]         Primary      Hamstring                       Bone Mulch Screw     WasherLoc                  Subtotal occlusion popliteal artery                    19 d                       Embolectomy               Preexistent intimal lesion after knee dislocation
  Janssen et al\[[@B47]\]         Primary      Hamstring                       Bone Mulch Screw     WasherLoc                  Pseudoaneurysm and occlusion popliteal artery          9 d                        Venous re-anastomosis     Drill tip for bicortical tibial fixation
  Milankov et al\[[@B48]\]        Primary      Hamstring                       Interference screw   Interference screw         Pseudoaneurysm med. inf. gen. artery                   1 d                        Ligation pseudoaneurysm   Hamstring harvest?
  Panigrahi et al\[[@B56]\]       Primary      Hamstring ACL + PCL             ?                    ?                          Occlusion popliteal artery                             Day of surgery             Embolectomy               Preexistent thrombotic occlusion after knee dislocation
  Tsubosaka et al\[[@B54]\]       Primary      Hamstring                       Cortical buttons     Screw post                 Pseudoaneurysm med. inf. gen. artery                   2 d                        Embolization              Anteromedial portal
  Pereira et al\[[@B39]\]         Revision     Hamstring                       Transverse screw     Interference screw         Pseudoaneurysm sup. lat. gen. artery                   2 d                        Ligation pseudoaneurysm   Hardware femur
  Carr et al\[[@B49]\]            Primary      Achilles tendon allograft       Interference screw   Suture+ washer bone plug   Traumatic arteriovenous fistula                        7 wk                       Ligation fistula          Injury at medial superior portal site

ACL: Anterior cruciate ligament; ACLR: ACL reconstruction; BPTB: Bone-patellar tendon-bone; PCL: Posterior cruciate ligament.

###### 

Data venous thromboembolism and thromboprophylaxis

  **Ref**.                        **Study design**   **Number ACLR**                          **Mean age** **(yr)**                                  **Male (M)** **Female (F)**                 **Graft type**                         **Mean duration surgery (min)**                 **Mean tourniquet time (min)**           **BMI** **(kg/m^2^)**                           **Thromboprophylaxis**                                                                                **Hospital stay (d)**
  ------------------------------- ------------------ ---------------------------------------- ------------------------------------------------------ ------------------------------------------- -------------------------------------- ----------------------------------------------- ---------------------------------------- ----------------------------------------------- ----------------------------------------------------------------------------------------------------- ----------------------------
  Marlovits et al\[[@B20]\]       RCT                140 (87 *vs* 88 placebo)                 29.9 ± 7.4 *vs* 30.2 ± 6.9                             M 63% F 60%                                 BTPB                                   Mean \> 120                                     ?                                        Comparable between groups                       Yes (enoxaparin 3-8 d + 20 d enoxaparin *vs* enoxaparin 3-8 d + placebo)                              3-8
  Mohtadi et al\[[@B21]\]         RCT                330                                      28.5 (14-50)                                           M 183 F 147                                 BPTB, hamstring                        ?                                               ?                                        ?                                               ?                                                                                                     ?
  Adala et al\[[@B6]\]            PC                 112                                      31.6                                                   M 61 F 51                                   Hamstring                              64.9 ± 7.8                                      ?                                        ?                                               None                                                                                                  2
  Cullison et al\[[@B10]\]        PC                 67                                       26.5 (19-39)                                           All men                                     BPTB                                   ?                                               83 (0-115)                               ?                                               None                                                                                                  ?
  Hirota et al\[[@B25]\]          PC                 30                                       24.1 ± 8.3                                             M 14 F 16                                   ?                                      ?                                               ?                                        ?                                               None                                                                                                  ?
  Hirota et al\[[@B22]\]          PC                 40 (20 ACLR *vs* 20 TKA)                 26.7 ± 13.4 *vs* 71.3 ± 6.8                            M:F ACLR 10:10 *vs* TKA 6:14                ?                                                                                      87.1 ± 24.4 *vs* 87.2 ± 18.4             ?                                               None                                                                                                  ?
  Lind et al\[[@B23]\]            PC                 5818                                     ?                                                      M approximately 57%                         BPTB and hamstring                     Prim. ACLR 69.4 ± 21.1; rev. ACLR 90.0 ± 32.3   ?                                        ?                                               18.5% (prim. ACLR 15.7%; rev. ACLR 20.8%)                                                             ?
  Maletis et al\[[@B11]\]         PC                 Prim. ACLR 15101                         Prim. ACLR 29.5 ± 11.5                                 M 9604 F 5497                               Autograft 57.6%, allografts 42.4%      ?                                               ?                                        ≥ 30 = 23.3%                                    ?                                                                                                     ?
                                                     Rev. ACLR 1091                           Rev. ACLR 29.8 ± 10.7                                  M 693 F 398                                 Autograft 20.9%, allografts 78.8%      ?                                               ?                                        ≥ 30 = 20.8%                                    ?                                                                                                     ?
  Struijk-Mulder et al\[[@B5]\]   PC                 100                                      30.0 ± 10.0                                            M 77 F 23                                   Autograft HS 84, BPTB 14 allograft 2   68.0 ± 22.0                                     76.0 ± 23.0                              25.0 ± 4.0                                      None                                                                                                  1 to 2
  Williams et al\[[@B24]\]        PC                 23                                       31 (19-42)                                             M 17 F 6                                    BPTB                                   ?                                               103 (89-136)                             ?                                               None                                                                                                  2-3
  Born et al\[[@B26]\]            RC                 136 ACLR + multiligament rec.            VTE group 42 (24-43); Non-VTE group 31 (SD 11)         DVT group M:F 3:0; Non-VTE group 103:28     ?                                      VTE group 152.0; Non-VTE group 233 ± 76         VTE group 78.0; Non-VTE group 102 ± 54   VTE group 35 (28-42); Non-VTE group 30 (SD 7)   Yes (before 2007, 3 wk aspirin. After 2007, LMWH 3 wk)                                                ?
  Dong et al\[[@B8]\]             RC                 152 ACLR                                 34.9                                                   M 91 F 61                                   Hamstring/allograft                    ?                                               3 groups \< 90, 90-120, \> 120           22.6                                            None                                                                                                  ?
  Ettema et al\[[@B27]\]          RC                 ?                                        ?                                                      ?                                           ?                                      ?                                               ?                                        ?                                               50% prescribed LMWH or coumarin during hospital stay; 5% for 1-2 wk; 2% for 3-4 wk and 35% for 6 wk   
  Gaskill et al\[[@B2]\]          RC                 15767 ACLR + HTO/PCL non specified       28.9 (SD 7.6)                                          M 13794                                     ?                                      ?                                               ?                                        27.8                                            ?                                                                                                     ? ?
  Hetsroni et al\[[@B30]\]        RC                 58863 ACLR, total 418323 arthroscopies   PE group 50.3 (15-79) *vs* non-PE group 45.5 (0-100)   F 2764 PE group F 57.3% *vs* non-PE group   ?                                      ?                                               ?                                        (SD 4.0) ?                                      ?                                                                                                     ?
  Jameson et al\[[@B28]\]         RC                 13941                                    29.3 (8-83)                                            F 46.8% M 79.5%                             ?                                      ?                                               ?                                        ?                                               ?                                                                                                     1-4
  Jaureguito et al\[[@B7]\]       RC                 131 group 1 (knee arthroscopy)           ?                                                      F 20.5% M 73                                \-                                     ?                                               ?                                        ?                                               Aspirin (325 mg) daily for 3 wk postsurgery if age \> 45 yr                                           ?
                                                     108 group 2 (ACLR, osteotomy)                                                                   F 58 M 60                                   ?                                      ?                                               ?                                        ?                                               Idem                                                                                                  ?
  Sun et al\[[@B29]\]             RC                 231                                      23.6                                                   F 48 M 69.3%                                ?                                      88.4                                            67.5                                     24.5                                            None                                                                                                  ?
  Ye et al\[[@B4]\]               RC                 171                                      30.1 ± 10.0                                            F 30.7% M 123                               Hamstring                              86.9 ± 26.4                                     69.9 ± 15.9                              24.4 ± 3.2                                      None                                                                                                  4
                                                                                                                                                     F 48                                                                                                                                                                                                                                                                                                                              
  Ackerman et al\[[@B55]\]        CR                 1                                        45                                                     F 1                                         BPTB                                   ?                                               0                                        ?                                               Aspirin 325 mg daily                                                                                  Outpatient
  Chien et al\[[@B50]\]           CR                 1                                        34                                                     M 1                                         ?                                      110                                             ?                                        30                                              none                                                                                                  ?
  Janssen et al\[[@B13]\]         CR                 1                                        19                                                     F 1                                         Hamstring                              96                                              110                                      27.5                                            LMWH during hospital stay                                                                             3
  Kang et al\[[@B51]\]            CR                 1 (+MCL rec.)                            48                                                     F 1                                         Hamstring                              ?                                               90                                       ?                                               None                                                                                                  ?
  Liu et al\[[@B52]\]             CR                 1                                        34                                                     M 1                                         Hamstring                              110                                             119                                      30.1                                            None                                                                                                  5
  Theron et al\[[@B53]\]          CR                 1                                        30                                                     F 1                                         ?                                      ?                                               ?                                        ?                                               ?                                                                                                     Occurred day after surgery

ACLR: ACL reconstruction; BPTB: Bone-patellar tendon-bone; TKA: Total knee arthroplasty; LMWH: Low molecular weight heparin; HTO: High tibial osteotomy; VTE: Venous thromboembolism; PCL: Posterior cruciate ligament; prim: Primary; MCL: Medial collateral ligament; rev: Revision; RCT: Randomized controlled trial; PC: Prospective cohort study; RS: Retrospective study; CR: Case report; SD: Standard deviation; DVT: Deep venous thrombosis; rec.: Reconstruction.

###### 

Incidence venous thromboembolism, risk factors and thromboprophylaxis recommendations

  **Ref**.                        **Study design**   **Incidence DVT (symptomatic if specified)**                                     **Incidence PE (symptomatic if specified)**   **Detection method VTE**                                                     **Risk factors DVT**                                                     **Thromboprophylaxis recommendations**
  ------------------------------- ------------------ -------------------------------------------------------------------------------- --------------------------------------------- ---------------------------------------------------------------------------- ------------------------------------------------------------------------ ----------------------------------------------------------------------------------
  Marlovits et al\[[@B20]\]       RCT                2 = 2.8% with extended prophylaxis; 28 = 41.2% without extended prophylaxis      0%                                            MRI venography                                                               Comparable between groups                                                Age \> 30, prolonged immobilisation and complex procedures
  Mohtadi et al\[[@B21]\]         RCT                1 (0.3%) symptomatic                                                             1 (0.3%) symptomatic                          Clinical, additional exam in suspected cases                                 None                                                                     \-
  Adala et al\[[@B6]\]            PC                 2 = 1.78% (1 pt symptomatic)                                                     0%                                            Ultrasound preop and day 2-3                                                 None                                                                     None if absent high risk factors DVT or age \< 45 yr
  Cullison et al\[[@B10]\]        PC                 1 = 1.5%                                                                         0%                                            Ultrasound preop, day 3 and 4 wk                                             None                                                                     None in male patients \< 40 yr and absence of risk factors
  Hirota et al\[[@B25]\]          PC                 0%                                                                               Peak emboli 50s after tourniquet release      Transoesophageal echocardiography                                            ?                                                                        \-
  Hirota et al\[[@B22]\]          PC                 0%                                                                               0%                                            Transoesophageal echocardiography                                            ?                                                                        \-
  Lind et al\[[@B23]\]            PC                 ?                                                                                ?                                             ?                                                                            ?                                                                        \-
  Maletis et al\[[@B11]\]         PC                 26 = 0.2% in primary ACLR                                                        15 = \< 0.1% in primary ACLR                  Various methods                                                              ?                                                                        ?
                                                     2 = 0.2% in revision ACLR                                                        0% in revision ACLR                           Idem                                                                         ?                                                                        ?
  Struijk-Mulder et al\[[@B5]\]   PC                 9 = 9.0% (symptomatic 4 = 4.0%)                                                  1 = 1%                                        Bilateral ultrasound                                                         Age, contraceptive use                                                   Further research for DVT prophylaxis, especially when risk factors are present
  Williams et al\[[@B24]\]        PC                 0%                                                                               0%                                            Bilateral ultrasound preop and 7-14 d postop                                 In 3 patients, non-specified                                             Future studies needed
  Born et al\[[@B26]\]            RC                 3 = 2.0% sympromatic                                                             ?                                             Clinical, ultrasound in suspected cases                                      Multiligamentous injury, age, history DVT                                In multiligament reconstruction. cf guidlines ACCP \"major orthopaedic surgery\"
  Dong et al\[[@B8]\]             RC                 17 = 8.5% (44.1% nonsymptomatic of all DVT cases = 12.1% of all patients)        ?                                             Color doppler ultrasound \< 24 h after admission and 3 and 7 d postsurgery   Multiligament reconstruction, tourniquet time \> 2 h, age                In case of PCL reconstruction and tourniquet time \> 2 h
  Ettema et al\[[@B27]\]          RC                 ?                                                                                ?                                             ?                                                                            ?                                                                        None
  Gaskill et al\[[@B2]\]          RC                 55 symptomatic                                                                   35                                            Clinical, additional exam in suspected cases                                 Age ≥ 35, smoking, cocomitant HTO/PCL surgery                            Further research for VTE prophylaxis
  Hetsroni et al\[[@B30]\]        RC                 ?                                                                                117 = 0.0003% all symptomatic                 Clinical, additional exam in suspected cases                                 Female gender, age, surgical time, previous cancer                       Further research for thromboprophylaxis in high risk patients
  Jameson et al\[[@B28]\]         RC                 42 = 0.3% all symptomatic                                                        25 = 0.8% all symptomatic                     Clinical, additional exam in suspected cases                                 Age \> 40                                                                No advise due to lack of evidence
  Jaureguito et al\[[@B7]\]       RC                 Retrospectively clinically 0.24% Prospectively 7 (2.9%, 5 asymptomatic = 2.1%)   0%                                            Duplex ultrasonography pre-operatively and 5 and 10 d postsurgery            None                                                                     \-
  Sun et al\[[@B29]\]             RC                 total 36 = 15.6% (4 prox DVT = 2.4%. Distal DVT 32 = 13.9%)                      0%                                            Venography day 3 postsurgery                                                 Age, multiligament surgery                                               None
  Ye et al\[[@B4]\]               RC                 24 = 14.0% (4 pts prox. DVT)                                                     0%                                            Chest X-ray and venography day 3 post ACLR                                   Female gender, age \> 35 yr                                              In female patients and age \> 35 yr
  Ackerman et al\[[@B55]\]        CR                 1 = 100%                                                                         0%                                            Clinical, ultrasound, CT and venography                                      May-Thurner Syndrome                                                     In case of high risk patient
  Chien et al\[[@B50]\]           CR                 ?                                                                                1 = 100%                                      Clinical, CT scan                                                            BMI, ACL surgery                                                         Further investigation for thromboprophylaxis after knee arthroscopy needed
  Janssen et al\[[@B47]\]         CR                 1 = 100%                                                                         1 = 100%                                      Clinical, transoesophageal echocardiography                                  Misdiagnosis DVT, Protein S deficiency? ACL surgery, contraceptive use   Further investigation for thromboprophylaxis after knee arthroscopy needed
  Kang et al\[[@B51]\]            CR                 1 = 100%                                                                         0%                                            Clinical, ultrasound                                                         Primary thrombocytopenia, Factor VIII, Proteine C and S                  None
  Liu et al\[[@B52]\]             CR                 1 = 100%                                                                         1 = 100%                                      Clinical, cardiac sonography                                                 BMI                                                                      Patients with increased risk and prolonged tourniquet time
  Theron et al\[[@B53]\]          CR                 ?                                                                                1 = 100%                                      Clinical, CT                                                                 Contraceptive use                                                        None

ACLR: ACL reconstruction; BPTB: Bone-patellar tendon-bone; TKA: Total knee arthroplasty; LMWH: Low molecular weight heparin; HTO: High tibial osteotomy; VTE: Venous thromboembolism; PCL: Posterior cruciate ligament; prim: Primary; RCT: Randomized controlled trial; PC: Prospective cohort study; RS: Retrospective study; CR: Case report; CT-scan: Computerized tomography-scan; BMI: Body mass index; DVT: Deep venous thrombosis; ACL: Anterior cruciate ligament; rec.: Reconstruction; pts: Patients; prox.: Proximal.

Results of individual studies and answers to research questions
---------------------------------------------------------------

**Arterial complications:** (1) What is the incidence of arterial complications after ACL reconstruction? Twenty-two studies reported arterial complications after ACL reconstruction. These papers described a total of 23 case reports. Arterial complications after ACL reconstruction are rare. The incidence of arterial lesions after ACL reconstruction is only described in 1 study. Janssen et al\[[@B45]\] have analysed their consecutive series retrospectively and found an incidence of 0.3% for arterial pseudoaneurysm in a series of 299 arthroscopic ACL reconstructions.

The incidence of arterial complications after ACL reconstruction is very low. The incidence of 0.3% presented in a retrospective series may be overestimated considering the fact that only case reports have been published in the literature. Long-term studies are necessary for analysis of the incidence of arterial complications after ACL reconstruction.

\(2\) What types of arterial complications occur after ACL reconstruction? Table [3](#T3){ref-type="table"} presents the details of the 23 published arterial complications after ACL reconstruction. The described complications were arterial-occlusions, avulsions, penetrating injuries, arteriovenous fistulae or pseudoaneurysms. Pseudoaneurysm was the most frequently reported arterial complication (13 cases). Various arteries around the knee were injured: Popliteal artery, posterior tibial artery, medial and lateral inferior genicular arteries and lateral superior genicular artery. Clinical presentations were repeated hemarthrosis, pain and a pulsatile mass after ACL reconstruction.

The types of arterial complications after ACL reconstruction may be categorized in arterial- occlusions, avulsions, penetrating injuries, arteriovenous fistulae or pseudoaneurysms. Pseudoaneurysm is the most common arterial complication (13/23 cases).

\(3\) Is there a correlation between arterial complications and fixation methods for ACL reconstruction? Twenty-three case reports on arterial complications have been published using various techniques of ACL reconstruction, detailed in Table [3](#T3){ref-type="table"}. There was no correlation between arterial complications and ACL reconstruction technique, methods of graft fixation or graft type. Eighteen studies reported that the vascular injury was caused by instruments during the ACL reconstruction (shaver, a drill bit for graft fixation, portal incision, previous catheterization and graft harvest). Pseudoaneurysm was the most frequently reported arterial complication after ACL reconstruction, irrespective of graft type or method of graft fixation. Four studies related their vascular complications to concurrent lateral meniscectomy, PCL reconstruction and preexistent intimal popliteal artery injury due to a previous knee dislocation.

No correlation was found between arterial complications and ACL reconstruction technique, methods of graft fixation or graft type.

\(4\) What is the time to diagnosis of arterial complications after ACL reconstruction? Six studies reported a time to diagnosis of 0-2 d after ACL reconstruction (Table [3](#T3){ref-type="table"}). All other studies showed a certain delay in diagnosis (1-7 wk postsurgery up to 8 years). Contrast-, CT- or MRI- angiographies are the diagnostic tools of choice\[[@B46]\]. Remarkably, most case reports described palpable dorsalis pedis and posterior tibial arterial pulses at time of clinical presentation with swelling and pain around the popliteal area. These findings have misled surgeons to underestimate vascular complications after ACL reconstruction. Prolonged follow-up and a high level of suspicion, with clinical symptoms of painful pulsating mass and sensory deficits in lower leg and foot, is mandatory in detecting these potentially devastating lesions. An immediate surgical exploration is imperative in limiting neurological damage\[[@B45]\]. Other than the Gore-Tex rupture ligament case\[[@B31]\], all patients maintained adequate ACL stability after vascular surgery. The neurological deficits however may be permanent.

The time to diagnosis of arterial complications after ACL reconstruction varies from days to mostly weeks but even years.

**Venous complications:** (1) What is the incidence of venous thrombo-embolism after ACL reconstruction without thromboprophylaxis? The incidence of VTE after ACL reconstruction without thromboprophylaxis varied from 1.5%-17.9%\[[@B1],[@B58]\]. The variable incidence of VTE after ACL reconstruction depended on the diagnostic methods of DVT (clinical parameters, venography, ultrasound or magnetic resonance venography) and the heterogeneity of patient demographics (age, risk factors, surgical time, concomitant surgery, tourniquet time and postoperative mobilisation). Eleven studies reported data of isolated ACL reconstruction without thrombophylaxis (Table [5](#T5){ref-type="table"}). The pooled total incidence of DVT was 9.7%, of which 2.1% was symptomatic. The pooled incidence of DVT in only low-risk bias studies was 10.6%. The pooled incidence of PE was 0.1% (Table [6](#T6){ref-type="table"}).

###### 

Incidence of venous thromboembolism

  **Ref**.                        **ACLR (*n*)**     **Incidence DVT (*n*)**   **Incidence sympt DVT (*n*)**   **Incidence PE** **(*n*)**   **Thromboprophylaxis**   **Risk of bias**
  ------------------------------- ------------------ ------------------------- ------------------------------- ---------------------------- ------------------------ ------------------
  Adala et al\[[@B6]\]            112                2                         1                               0                            No                       Low
  Cullison et al\[[@B10]\]        67                 1                                                         0                            No                       \-
  Dong et al\[[@B8]\]             152                11                                                        NA                           No                       \-
  Jamesonet al\[[@B28]\]          13941              42                        42                              25                           NA                       \-
  Maletis et al\[[@B11]\]         15101              26                                                        15                           NA                       \-
  Marlovits et al\[[@B20]\]       140 (72 *vs* 68)   2 *vs* 28                                                 0                            Yes                      \-
  Mohtadi et al\[[@B21]\]         330                1                         1                               1                            NA                       \-
  Struijk-Mulder et al\[[@B5]\]   100                9                         4                               1                            No                       Low
  Sun et al\[[@B29]\]             231                36                                                        0                            No                       Low
  Williams et al\[[@B24]\]        23                 0                         0                               0                            No                       \-
  Ye et al\[[@B4]\]               171                24                                                        0                            No                       \-

Pooled incidence: All DVT: 79/14093 = 9.7%; symptomatic DVT: 5/235 = 2.1%; all DVT of low risk bias studies: 47/443 = 10.6%; PE = 1/704 = 0.1%. ACLR: Anterior cruciate ligament reconstruction; DVT: Deep venous thrombosis; sympt: Symptomatic; PE: Pulmonary embolism; NA: Not applicable.

After ACL reconstruction without thromboprophylaxis, the incidence of DVT is 9.7%, of which 2.1% is symptomatic. The incidence of PE is 0.1%.

\(2\) Is tourniquet time related to VTE after ACL reconstruction? Eight studies that were evaluated by risk of bias analysis documented tourniquet time in ACL reconstruction. This varied from 67.5 min to \> 2 h. Deep venous thrombosis was more frequent with tourniquet time \> 2 h. Extended tourniquet time was associated with combined ACL reconstruction and concomitant surgery. The incidence of DVT among patients with tourniquet lasting \> 2 h increased from 12.1% to 17.4%\[[@B1],[@B58]\]. In these cases, thromboprophylaxis was recommended with \> 2 h tourniquet time.

Tourniquet time \> 2 h is related to VTE after ACL reconstruction.

\(3\) Is thromboprophylaxis indicated after ACL reconstruction? Eight studies made recommendations for thromboprophylaxis after knee ligament surgery. No thromboprophylaxis was deemed necessary in case of isolated ACL reconstruction in patients without risk factors. Risk factors for VTE were those reported in the ACCP guidelines\[[@B59]\], female gender, \> 30 years of age, complex or concomitant surgical procedures, prolonged immobilization and tourniquet time \> 2 h. Further research on thromboprophylaxis is recommended by most authors.

Thromboprophylaxis is indicated in patients considered to be at moderate or high risk of VTE\[[@B20]\].

DISCUSSION
==========

The most important finding of the present study is that after ACL reconstruction, the incidence of arterial complications, symptomatic DVT and PE was 0.3%, 2.1% and 0.1% respectively. The incidence of 0.3% of arterial complications may be overestimated considering the fact that only case reports have been published in the literature. However, the pooled incidence of DVT after ACL reconstruction without thromboprophylaxis was 9.7%, of which 2.1% of patients was symptomatic.

Pseudaneurysms were the most frequently reported arterial complication after ACL reconstruction, irrespective of graft type or method of graft fixation. Pseudoaneurysms differ from true aneuryms in that they do not contain all the layers of an artery. They resemble organized hematomas that have internal arterial flow\[[@B1]\]. A direct arterial trauma by a drill bit, shaver, hardware or fixation device for ACL reconstruction may cause a pseudoaneurysm. This condition usually presents with repeated hemarthrosis and a pulsatile mass within days to weeks after ACL reconstruction. Their growth may lead to neuropraxia and DVT due to compression of nerves and nearby veins, respectively\[[@B1]\]. Patients with poor collateral development may have severe ischemia and poor prognosis, even leading to amputation\[[@B1],[@B35],[@B38]\].

Krupp et al\[[@B60]\] analysed the safety of femoral cross-pin in ACL reconstruction. They concluded that insertion angle, not tunnel drilling method, influenced saphenous nerve and femoral artery/vein injury at risk\[[@B60]\]. Post et al\[[@B61]\] studied the relative position of the neurovascular structures at risk when drilling bicortical screws for tibial fixation in ACL reconstruction\[[@B45]\]. Arthroscopic tibial tunnels were made in cadaver human knees using lateral X-rays for accurate positioning. A 4.5 mm bicortical drill hole was placed perpendicular to the tibial surface 1 cm distal to the tibial tunnel. The distances from the posterior tibial drill exit point to the nearby neurovascular structures were measured with a caliper. The closest structure to the exit point was the bifurcation of the popliteal artery/vein (11.4 ± 0.6 mm). The next closest was the anterior tibial vein (11.7 ± 1.6 mm). The closest any individual hole came to a neurovascular structure was 3.5 mm from the anterior tibial vein. They concluded that bicortical screw and spiked washer fixation of soft tissue ACL grafts appears to be relatively safe\[[@B45],[@B61]\]. Curran et al\[[@B58]\] performed an *in vitro* study comparing 2 techniques for ACL tibial fixation with a bicortical screw. They concluded that aiming the screw towards the fibula reduced the risk of vascular injury compared to screws drilled perpendicular to the cortex. Other possible recommendations to prevent neurovascular damage are the use of a drill bit stop for bicortical screws or a single cortex fixation on the tibia without compromising stability of fixation\[[@B1]\]. The incidence of arterial complications in the present review (0.3%)\[[@B45]\] was updated in a consecutive series of 1961 ACL reconstructions with hamstring autografts and bicortical tibia fixation by the same authors\[[@B1]\]. The incidence was reduced from 0.3% to 0.15% after the safety measures were applied as suggested by Janssen et al\[[@B1]\] and Curran et al\[[@B58]\].

A high level of suspicion, with clinical symptoms of painful pulsating mass and sensory deficits in lower leg and foot, is mandatory in detecting these potentially devastating lesions. The differential diagnosis should include compartment syndrome and DVT\[[@B47]\]. Doppler examination and intact dorsal pedal and posterior tibial pulses are unreliable in diagnosing arterial lesions after ACL reconstruction\[[@B47]\]. Contrast-, CT- or MRI- angiographies are the diagnostic tools of choice\[[@B45],[@B46]\]. Surgical exploration and vascular repair (or ligation/embolization of the feeding vessel) remain standard management\[[@B45],[@B46]\]. An immediate surgical exploration is imperative in limiting neurological damage\[[@B1],[@B45],[@B46]\].

A meta-analysis of DVT after knee arthroscopy without thromboprophylaxis found an overall DVT rate of 9.9% (3.1%-17.9%) when routine screening using ultrasound or contrast venography was used\[[@B13]\]. Proximal DVT rate was 2.1% (0%-4.9%)\[[@B13],[@B62]\]. Proximal DVT may progress to PE, however the clinical significance of distal DVT remains questionable\[[@B62]-[@B64]\]. Sun et al\[[@B29]\] found that the total incidence of VTE, diagnosed with venography on the third day after arthroscopic knee surgery, was 14.9%, of which only 3.7% were symptomatic. Delis et al\[[@B14]\] found 50% of the DVT patients to be completely asymptomatic. They also examined the history of DVT if treated (aspirin in calf DVT, heparin-warfarin in proximal DVT)\[[@B13]\]. Following early diagnosis, total clot lysis was documented in 50% and partial clot lysis in the remaining 50%, within 118 d median follow-up. Segmental venous reflux developed in at least 75% of the legs sustaining thrombosis. A previous thrombosis or the presence of two or more risk factors for thromboembolism significantly increased the incidence of DVT. No symptoms or signs of PE were documented\[[@B13],[@B14]\].

The current review showed that after ACL reconstruction without thromboprophylaxis, the incidence of DVT was 9.7%, of which 2.1% was symptomatic. The incidence of PE was 0.1%. These findings are similar to the conclusions by Erickson et al\[[@B3]\]. They described an 8.4% rate of DVT after ACL reconstructions in patients without postoperative thromboprophylaxis (73% was asymptomatic), while the rate of symptomatic PE was 0.2%\[[@B3]\]. Maletis et al\[[@B11]\] described symptomatic DVT in 0.2% of 16192 primary and revision ACL surgeries. However, the authors did not specify the use of thromboprophylaxis\[[@B11]\]. Cullison et al\[[@B10]\] and Adala et al\[[@B6]\] found comparable rates of DVT of 1.5% and 1.8% respectively using prospective pre- and postoperative ultrasonography in patients without VTE risk factors. The authors recommended that thromboprophylaxis is not necessary in the absence of risk factors in patients younger than 45 years of age with early postoperative mobilization\[[@B6]\]. In a study of 282 Chinese patients, the incidence of DVT was 12.1% after ACL reconstruction. Tourniquet time \> 2 h and concomitant PCL reconstructions were risk factors for DVT\[[@B8]\]. Ye et al\[[@B4]\] found that the incidence of DVT was 14%, diagnosed by unilateral venography on the third day after ACL reconstruction. Proximal DVT occurred in 16.7% of DVT patients. None of the DVT patients developed PE. The authors recommended thromboprophylaxis in female patients and patients older than 35 years\[[@B4]\]. The described variable incidence of VTE after ACL reconstruction depends on the diagnostic methods of DVT (clinical parameters, venography, ultrasound or magnetic resonance venography) and the heterogeneity of patient demographics (age, risk factors, surgical time, concomitant surgery, tourniquet time and postoperative immobilization).

The use of a tourniquet improves operative visualisation during arthroscopic ACL reconstruction\[[@B65],[@B66]\]. Various authors reported that tourniquet time in excess of 90 min increased the rates of VTE\[[@B8],[@B17],[@B30],[@B67]\]. Smith et al\[[@B65]\] published a meta-analysis of tourniquet assisted arthroscopic knee surgery. There was no difference in complication rate if tourniquet time exceeded 60 min. Hirota e*t al*\[[@B22],[@B25]\] quantified pulmonary emboli after tourniquet release in patients during ACL reconstruction (extramedullary) *vs* total knee arthroplasty (intramedullary procedure)\[[@B13]\]. They chose these two groups for having more than 60 min tourniquet time and detected pulmonary emboli in all patients after release of the tourniquet using transesophageal echocardiography with a peak at 30-40 s postrelease\[[@B13]\]. The amount of emboli was defined as percentage of total emboli formed in relation to the right atrial area. This percentage returned to baseline levels 2 min after tourniquet release in the ACL group. They found a significant linear correlation between the amount of emboli and duration of tourniquet inflation in the ACL group. In comparison, the total knee arthroplasty group had a significant larger amount of emboli (4-5 fold) with no return to baseline levels during the assessment period. No patient in either group showed signs of PE\[[@B13],[@B22],[@B25]\]. In a recent systematic review, Papalia et al\[[@B66]\]. concluded that a tourniquet can be used safely, provided that the inflation pressure is not excessive and tourniquet time is less than 2 h.

Asymptomatic pulmonary emboli occur in all patients with ACL reconstructions after tourniquet release\[[@B1],[@B13]\]. Furthermore, PE may occur as a result of proximal DVT\[[@B13],[@B24],[@B50],[@B52]\]. Hetsroni et al\[[@B30]\] analysed 418323 arthroscopic knee procedures and found an incidence of 0.03% for symptomatic PE. Risk factors were female sex, age, history of cancer and prolonged operating time (\> 90 min). In spite of improved prevention and treatment of PE, the mortality is still estimated to be 20%-30%\[[@B68]\]. It is the third most common cardiovascular cause of death, with 2/3 of the death occurring within the first few hours as a result of severe hemodynamic and respiratory disturbances\[[@B53],[@B68],[@B69]\]. Janssen et al\[[@B1],[@B13]\] found an incidence of fatal PE of 0.05% in a consecutive series of 1961 arthroscopic ACL reconstructions\[[@B1]\]. Risk factors were preexistent coagulopathy, oral contraceptive medication and delay in DVT diagnosis.

Thromboprophylaxis after ACL reconstruction remains controversial\[[@B1],[@B9],[@B16],[@B27],[@B50],[@B52],[@B59],[@B70],[@B71]\]. Geerts et al\[[@B59]\] reviewed the evidence-based literature for thromboprophylaxis in knee arthroscopy and only recommend prophylaxis with Low Molecular Weight Heparin in patients with risk factors for VTE (Grade 2B level of evidence). Risk factors in their study were history of DVT, age ≥ 40 years, surgical time \> 60 min. and a complicated/prolonged procedure\[[@B59]\]. Additional risk factors for VTE after ACL reconstruction in other studies on VTE were smoking, oral contraceptive use or hormone replacement, BMI \> 30 kg/m^2^, chronic venous insufficiency, cancer and thrombophilic conditions\[[@B1],[@B12],[@B14],[@B30],[@B52],[@B59],[@B64],[@B72]\]. In a randomized controlled trial, Marlovits et al\[[@B20]\] concluded that extended duration of thromboprophylaxis with enoxaparin by an additional 20 d significantly reduced venographically detected DVT after ACL reconstruction without an increase in major bleeding compared to enoxaparin limited to in-hospital thromboprophylaxis for 3-8 d. The authors found a 41.2% incidence of DVT for discharged patients who had a placebo as postdischarge thromboprophylaxis in contrast to 2.8% in the thromboprophylaxis group. Risk factors for DVT were age over 30 years, prolonged immobilization and surgical time\[[@B20]\]. It should be noted that their mean surgical time as a teaching hospital (\> 2 h) as well as their hospital stay of 3-8 d do not reflect most current ACL surgery practices with early discharge and mobilization. A Cochrane systematic review on interventions for preventing VTE in adults undergoing knee arthroscopy reported that no strong evidence was found to conclude that thromboprophylaxis is effective to prevent VTE in people with unknown risk factors for thrombosis\[[@B20],[@B68],[@B70]\]. This is confirmed by other recent studies on DVT prophylaxis after ACL reconstruction and knee arthroscopic procedures\[[@B2],[@B17],[@B64]\]. It is now common practice in a surgical setting to use a risk-assessment model, such as the one developed by Capriani et al\[[@B20]\]. Patients considered to be at moderate or high risk of VTE should routinely receive thromboprophylaxis\[[@B1]\]. However, recommendations for the best type and duration of prophylaxis after ACL reconstruction still need to be defined\[[@B5]\]. In spite of the scientific effort to date, no recommendations for routine thromboprophylaxis in ACL reconstruction can be provided in the absence of risk factors for VTE\[[@B1],[@B13]\]. Further investigation is required to analyse actual incidence and severity of venous thromboembolism as well as the efficacy-to-bleeding tradeoff for routine thromboprophylaxis after ACL reconstruction in patients without risk factors for VTE\[[@B1],[@B13]\].

This systematic review has several limitations. In the search for the available knowledge on vascular complications, studies of various level of evidence were included. Another weakness of this review is the inclusion of studies with small population size. Both the quality and limited amount of studies for specific research questions may limit the level of evidence for this review. Although strict and adapted for various study types, the risk of bias assessment of the Cochrane Library and the classifications of "low", "questionable" and "high" risk of bias for the studies may limit the strength of evidence. One might argue that a "low" risk of bias RCT study is of higher level of evidence than a "low" risk of bias prospective cohort study. Another weakness of this study is that only articles in English were included. Additional relevant articles published in languages other than English could contribute to the level of evidence presented in this review.

The clinical relevance of this review is that patients undergoing ACL reconstruction may be informed that vascular complications can occur with any type of reconstruction and that thromboprophylaxis should be prescribed in patients with risk factors for VTE.

After ACL reconstruction, the incidence of arterial complications, symptomatic DVT and PE was 0.3%, 2.1% and 0.1% respectively. Arterial complications may occur with all types of arthroscopic ACL reconstruction, methods of graft fixation as well as any type of graft. Patients considered to be at moderate or high risk of VTE should routinely receive thromboprophylaxis after ACL reconstruction.

COMMENTS
========

Background
----------

A thorough understanding of the incidence, risk factors and potential methods for prevention of vascular complications after anterior cruciate ligament (ACL) reconstruction is critical to optimize patient safety. This systematic review presents the current knowledge of arterial complications, venous thromboembolism (VTE) and thromboprophylaxis after arthroscopic ACL reconstruction. The review highlights the incidence, types and risk factors of arterial complications and VTE after ACL reconstruction as well as the current recommendations for deep venous thrombosis prophylaxis.

Research frontiers
------------------

This systematic review is related to research on thromboprophylaxis after ACL reconstruction.

Innovations and breakthroughs
-----------------------------

This review presents a systematic overview of the incidence and type of arterial complications after ACL reconstruction. Such an overview has not been presented previously. Furthermore, an overview of the incidence, risk factors and indications for thromboprophylaxis after ACL reconstruction are presented. There is a need for this current knowledge due to the controversy in this field of research. Suggestions for further research are presented in the study.

Applications
------------

Clinical implications are presented for adequate diagnosis and treatment of vascular complications after ACL reconstruction. Risk factors and indications for thromboprophylaxis are discussed.

Terminology
-----------

All terminology is explained in the manuscript.

Peer-review
-----------

This is an interesting systematic review that aims to evaluate the arterial and venous complications, by analyzing the relevant studies.
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